Impact of Tomotherapy on Xerostomia and Quality of Life of Patients With Cancer of the Upper Aero-digestive Tract (TOQUAL)

Centre Francois Baclesse

Status and phase: Terminated; Phase 2

Conditions: With or Without Concurrent Chemotherapy; Radiotherapy by Tomotherapy Exclusive; Head and Neck Cancer

Treatments: Radiation: Tomotherapy

Study type: Interventional

Funder types: Other

Identifiers

NCT01548846

TOQUAL

Details and patient eligibility

About

This is a study whose main objective is to evaluate prospectively the proportion of patients with severe xerostomia one year after treatment with tomotherapy for head and neck cancer.

Enrollment: 11 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient (e) old (e) over 18 years
• Patients with squamous cell carcinoma of head and neck (oral cavity, oropharynx, lymphadenopathy without gateway) histologically proven.
• Patient targeted for head and neck radiotherapy by Tomotherapy exclusive with or without concurrent chemotherapy (containing platinum)
• Indication of head and neck radiotherapy bilateral
• All of the TNM stage except metastatic
• Patient has signed informed consent for participation in the study
• Mastery of the French language

Exclusion criteria

• History of head and neck radiotherapy
• Indication of head and neck radiotherapy unilateral
• Personal history of malignant tumors uncontrolled over the past 5 years
• History of oral sicca syndrome
• Surgical removal of one or more salivary glands (parotid, submandibular gland, sublingual gland)
• Concomitant treatment with amifostine
• Concomitant treatment with cetuximab
• Primary tumor of the salivary glands
• Head and neck hyperfractionated radiotherapy and / or accelerated
• Head and neck radiotherapy hypofractionated
• Metastatic disease
• Patient deprived of liberty, under guardianship
• Any medical condition or psychological associate that could compromise the patient's ability to participate in the study
• Refusal of the patient.